List view / Grid view
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
The developers of an RNA imaging technology are using it to create a COVID-19 coronavirus testing kit, able to recognise the viral genome.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
Researchers have identified that copper ions and their protein transporters, such as Atox1, are key to cancer cell movement and could be targeted by therapies.
Researchers have developed a novel affordable and reproducible assay to study the malaria parasite, using a new cytoplasmic dye, Cell Trace Far-Red (CTFR).
Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you.
